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Abstract
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a mutation in one copy of
the neurofibromin gene (NF1+/−). Even though approximately 40–60% of children with NF1 meet the criteria for
attention deficit hyperactivity disorder (ADHD), very few preclinical studies, if any, have investigated alterations in
impulsivity and risk-taking behavior. Mice with deletion of a single NF1 gene (Nf1+/−) recapitulate many of the
phenotypes of NF1 patients.
Methods: We compared wild-type (WT) and Nf1+/− mouse strains to investigate differences in impulsivity and hyperactivity
using the delay discounting task (DDT), cliff avoidance reaction (CAR) test, and open field. We also investigated whether
treatment with the clinically effective alpha-2A adrenergic receptor agonist, guanfacine (0.3 mg/kg, i.p.), would reverse
deficits observed in behavioral inhibition.
Results: Nf1+/− mice chose a higher percentage of smaller rewards when both 10- and 20-s delays were administered
compared to WT mice, suggesting Nf1+/− mice are more impulsive. When treated with guanfacine (0.3 mg/kg, i.p.), Nf1+/−
mice exhibited decreased impulsive choice by waiting for the larger, delayed reward. Nf1+/− mice also exhibited deficits in
behavioral inhibition compared to WT mice in the CAR test by repetitively entering the outer edge of the platform where
they risk falling. Treatment with guanfacine ameliorated these deficits. In addition, Nf1+/− mice exhibited hyperactivity as
increased distance was traveled compared to WT controls in the open field. This hyperactivity in Nf1+/− mice was reduced
with guanfacine pre-treatment.
Conclusions: Overall, our study confirms that Nf1+/− mice exhibit deficits in behavioral inhibition in multiple contexts, a key
feature of ADHD, and can be used as a model system to identify alterations in neural circuitry associated with symptoms of
ADHD in children with NF1.
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Background
Neurofibromatosis type 1 (NF1) is an autosomal domin-
ant disorder with a mutation in one copy of the neurofi-
bromin gene (Nf1+/−) and has a prevalence of
approximately 1 in 3000 individuals [1–9]. NF1 encodes
neurofibromin, a well-known GTPase-activating protein
(GAP) that negatively regulates p21ras (RAS) activity
[10–16]. NF1-mediated RAS pathophysiology in the cen-
tral nervous system plays a role in cognitive behaviors
[3, 17–20]. Hyperactivation of the RAS pathway in
Nf1+/− mice is known to lead to various disruptions of
neurotransmitter systems and synaptic plasticity that
may underlie deficits observed in cognitive behaviors
related to ADHD. The clinical presentations in NF1
patients are highly variable in severity with about 20
to 40% developing benign tumors [21]. Furthermore,
individuals with NF1 suffer from significant incidence
of cognitive difficulties and are frequently diagnosed
with learning disabilities, attention deficit hyperactiv-
ity disorder (ADHD), and autism spectrum disorders
[22–25]. Even though approximately 40–60% [5] of
children with NF1 meet the criteria for ADHD, very
few preclinical studies have investigated the role of
NF1 mutation on ADHD phenotypes.
ADHD is one of the most frequently diagnosed neuro-
developmental disorders with an occurrence of approxi-
mately 5% in children worldwide [26–28]. The DSM-5
classifies ADHD as a patient exhibiting a persistent pat-
tern of inattention and/or hyperactivity–impulsivity that
interferes with functioning or development (American
Psychiatric Association. Diagnostic and Statistical Man-
ual of Mental Disorders, Fifth Edition. 2013). Several as-
pects of attention (intensive, selective, and executive) are
impaired in NF1 patients with ADHD [29]. In addition,
a common manifestation of ADHD in NF1 patients is
executive dysfunction including impairments in response
inhibition [2, 30–32]. ADHD symptoms have a negative
impact on the intellectual development of children with
NF1 [33]. Individuals with NF1 diagnosed with ADHD
also have decreased alertness, reduced visuospatial skills,
and impaired cognitive flexibility compared to healthy
controls [29]. For instance, in a classic stop signal re-
sponse inhibition test, during the stop signal task, NF1
patients with or without ADHD needed a significantly
longer stop signal delay in order to inhibit their pre-
potent response [34]. In studies, which do not stratify
NF1 patients based on an ADHD diagnosis but measure
ADHD phenotypes, NF1 patients exhibit greater inci-
dence of impulsivity and hyperactivity [19, 35]. When
tested for impulsivity, individuals with NF1 commit
more errors and respond faster than control participants
in the Go/No-Go task [35]. Indeed, NF1 children react
to a target appearance more quickly (short reaction
time) and commit more errors compared to control
children suggesting increased impulsivity and inattention
[2]. Finally, NF1 children have worse outcomes com-
pared to control children on tasks of spontaneous and
reactive cognitive flexibility [36]. These studies reflect
the significant impact of ADHD in NF1 patients.
Using NF1 mutant strains of mice, investigators have
been able to observe cognitive and behavioral deficits
like those commonly seen in children diagnosed with
NF1 [5, 20, 37]. Our previous studies have found that
Nf1+/− mice exhibit deficits in long-term social learning
in the three-chamber preference test [20]. Furthermore,
we have found that Nf1+/− mice have reduced neurofi-
bromin levels and RAS-MAPK/ERK hyperactivation in
many key brain regions as well as disrupted amygdala
synaptic plasticity [20]. Using Nf1+/− mice that have in-
activation of the neurofibromin gene within astroglial
cells (specifically GFAP+ cells), known as Nf1+/− OPG
mice, Brown and colleagues found impairments in
spatial learning and memory [38]. This group also ob-
served that Nf1+/− OPG mice have deficits in attention
that can be restored by administration of methylphenid-
ate or L-3,4-dihydroxyphenylalanine, but these mice do
not display hyperactivity [38]. Previous studies have also
found that Nf1+/− male mice exhibit deficient pre-pulse
inhibition (PPI), a deficit observed in children with
ADHD [39, 40]. Using Nf1+/− male mice provides strong
construct validity for this autosomal dominant disorder.
This study will be the first preclinical study to investi-
gate deficits in behavioral inhibition and impulsivity in a
NF1 preclinical model.
Impulsive choice has significant and enduring conse-
quences for individuals with ADHD, and thus, effective
treatment for impulsivity is of highest importance. Me-
thylphenidate (MPH) and other stimulant medications
are commonly used to treat short-term impulsivity in
ADHD individuals. However, these medications work in
some, but not all children with NF1 diagnosed with
ADHD. Also, due to side effects and abuse potential of
stimulant medications, there are additional factors that
contribute to the need for alternative approaches to
treating these subjects with agents such as guanfacine.
Furthermore, Omrani et al. found that preclinical
models of NF1 have alterations in hyperpolarization-
activated cyclic nucleotide-gated channel 1 (HCN) chan-
nels, suggesting guanfacine may be particularly effective
in treating ADHD in NF1 due to its effects on HCN
channels in the prefrontal cortex [41]. Therefore, the
current study tested the effects of guanfacine (an alpha-
2a (α2A) adrenergic receptor agonist), which is a non-
stimulant used to treat ADHD patients, in a clinically
relevant experimental model of NF1. Overall, these stud-
ies may help to elucidate the molecular mechanisms of
impulsivity and inhibition that can be used to develop
better treatments and diagnostics for patients with NF1.
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Methods
Animals
All experiments were conducted using adult WT and
Nf1+/− male mice (3–4 months old) that were bred on a
C57BL/6J background for over 10 generations. Each co-
hort was made up of littermates with 2–4 litters used
per experimental group. The original Nf1+/− mice were
obtained from Tyler Jacks at the Massachusetts Institute
of Technology (Cambridge, MA). The breeding scheme
for these mice consisted of trios with one WT male on a
C57BL/6J background and two Nf1+/− females on
C57BL/6J background. Once weaned (postnatal day 28),
all mice were group-housed (3–4/cage by litter contain-
ing mixed genotypes), given food and water ad libitum,
and maintained on a 12-h light-dark cycle (7:00 am/7:00
pm) at 72 °F. Each behavioral task was done in separate
cohorts of animals. Only males were used in these stud-
ies because in the general population, males are at a 3:1
higher risk to develop ADHD compared to females.
Furthermore, we have observed very few phenotypic dif-
ferences in Nf1+/− females compared to WT controls.
However, future experiments will examine ADHD-like
phenotypic behavior in female Nf1+/− mice. Animal care
procedures were conducted in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
(NIH Publication No. 80-23) revised 1996. All proce-
dures have been approved by the Indiana University
School of Medicine Institutional Animal Care and Use
Committee (Protocol No. 11082).
Drugs
Guanfacine (GUAN, 0.1 and 0.3 mg/kg, i.p [42–45]) was
obtained from Sigma (St. Louis, MO), dissolved in 0.9%
saline (vehicle, VEH), and administered in a volume of 1
mL/kg. Previous literature has found that a range of 0.1
to 0.3 mg/kg is an effective dose of GUAN to reduce
locomotion and measures of impulsivity in rodents that
are not confounded by sickness and significant sedation
[44, 45]. Therefore, we used a different cohort of mice
for each behavioral task and investigated the effects of
two doses of GUAN (0.1 and 0.3 mg/kg) that are based
on the literature. These doses of GUAN in mice are
comparable to the doses used for children with ADHD
([46]; FDA ref# 3335794). To ensure observers were
blind to treatment conditions, vials were letter-coded
prior to administration by a person not involved in the
running of each experiment.
Behavioral tests
Open field test
For Experiment 1, mice (n = 7–8/genotype) were placed
into the center of a square open field arena (40 × 40 cm,
30 cm height) [20]. The behavior of each mouse in the
open field arena was recorded for 60 min on video and
scored afterwards using the AnyMaze automated soft-
ware (AnyMaze, Stoelting, Wood Dale, IL). To ensure
observers were blind to genotype conditions, video files
were letter coded prior to behavioral scoring. The total
distance traveled (m) was scored. Behavior was analyzed
in 10-min increments as well as the entire 60-min test-
ing period. For Experiment 2, VEH (n = 8/genotype), 0.1
mg/kg GUAN (n = 6–8/genotype), and 0.3 mg/kg GUAN
(n = 9/genotype) were administered to separate sub-
groups of mice daily for 5 days and then 30 min prior to
open field testing. Due to technical difficulties with some
of the videos, the total animal numbers in the open field
were reduced from 9 to 8 in both WT and Nf1+/− ge-
notypes in the VEH treatment groups and reduced
from 9 to 6 in the WT 0.1 mg/kg GUAN group and
8 in the Nf1+/− 0.1 mg/kg GUAN group.
Cliff avoidance reaction (CAR)
A separate set of mice were used in the cliff avoidance
reaction (CAR) test. Methods for the CAR were based
on those described by Yamashita et al. [47]. For Experi-
ment 1, a round, plastic platform (diameter, 20 cm;
thickness, 2 cm) supported by a plastic rod (height, 50
cm) was used to assess CAR. The platform was stabi-
lized by a rectangular piece of plastic (26 cm × 38 cm)
and set in a kiddie pool with a rubber bottom to help
prevent injury if the animal fell. At the beginning of the
test, mice (n = 6–7/genotype) were gently placed in the
center of the platform and behavior was recorded for
60 min. If a mouse fell from the platform, it was imme-
diately placed back on the platform and the test is con-
tinued until 60 min had elapsed. A mouse was
considered to have impaired CAR if it fell from the
platform. CAR was calculated as % of mice which dem-
onstrated intact CAR for each group: % of mice with in-
tact CAR = [the number of mice that did not fall from
the platform/total number of mice] × 100. Total dis-
tance traveled, number of entries into the edge zone,
and number of entries into the over the edge zone were
recorded and scored with the automated AnyMaze soft-
ware. The edge zone was defined by outlining the outer
1 inch of the round platform with one inner circle and
one outer circle in the AnyMaze software. The over the
edge zone was defined by outlining an outer circle that
was 2 inches from the edge of the platform in the Any-
Maze software. During the testing period, ataxia and
stereotypy were assessed and manually scored by an ob-
server blind to the treatment conditions. To ensure ob-
servers were blind to genotype conditions, video files
were letter-coded prior to behavioral scoring. For Experi-
ment 2, VEH (n = 8–9/genotype), 0.1 mg/kg GUAN (n =
9/genotype), and 0.3 mg/kg GUAN (n = 9/genotype) were
administered to a separate group of mice daily for 5 days
and then 30 min prior to CAR testing.
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Measurement of ataxia and stereotypy
At the 30-min time point during the CAR test session in
Experiment 1, both ataxia and stereotypy behavior were
assessed for 1 min. We assessed ataxic and stereotypy
behavior during the CAR test to replicate methods from
Yamashita et al [47]. Ataxic behavior was scored using
the same numerical rating scale that was developed by
Hiramatsu and colleagues in 1989; the following num-
bers were used according to the behavior [47, 48]: “(0)
inactive or coordinated movements, (1) awkward or
jerky movements or loss of balance while rearing, (2) fre-
quent falling or partial impairment of reflexes, (3) inabil-
ity to move beyond a small area and support of body
weight on haunches or abdomen, and (4) inability to
move except for twitching movements”. For stereotypy
scored from video images by an observer blinded to the
treatment conditions, we used a rating scale used by
Creese and Iversen [49] and Yamashita et al. [47]: “(0)
asleep or stationary, (1) active, (2) predominantly active
but with bursts of stereotypic sniffing or rearing, (3)
stereotypic activity such as sniffing along a fixed path on
the test ground, (4) stereotypic sniffing or rearing main-
tained in one location, (5) stereotypy in one location
with bursts of gnawing or licking, and (6) continual
gnawing or licking”. For Experiment 2, VEH (n = 8–9/
genotype), 0.1 mg/kg GUAN (n = 9/genotype), and 0.3
mg/kg GUAN (n = 9/genotype) were administered daily
for 5 days and then 30 min prior to CAR testing.
Delay discounting test
Methods for the delay discounting test (DDT) were
adapted from the protocol described from Freund and
colleagues [50] and are illustrated in Fig. 3a. For Experi-
ment 1, a separate set of animals (n = 6–8/genotype)
were trained to run down an arm of a t-maze (each arm
measured 36 cm length, 8 cm width, and 12.5 cm height;
the entire apparatus elevated 6 cm) to receive either a
small reward (1 Cocoa Krispies cereal) in one arm or a
large reward (4 Cocoa Krispies) in the other arm. The
number of days it took for the animal to learn to choose
the large reward over the small reward was recorded.
Animals were trained until they met a set criterion of
choosing the large reward at least five out of six trials on
two consecutive days (a total of 12 rewards maximum).
During training, after the mouse makes a choice of an
arm, a clear barrier is lowered so that the mouse remains
in that arm while eating the chosen reward. Once sub-
jects reached this criterion, a delay period of 10 or 20 s
was initiated for the large reward while the small reward
was available immediately. This testing period lasted 6
days. The number of testing days were based on the
methods from Olmstead et al. [51], and other laborator-
ies have shown this amount of testing days to sufficiently
detect group differences [52]. Based on previous
literature, different groups of animals were used for each
delay condition to ensure there were no carryover effects
between delay conditions [50]. The 0 delay measure is
when the animals meet the criteria of choosing the large
reward 10 out of 12 trials across two days and, therefore,
refers to the number of small rewards chosen on day 1
and day 2 prior to the testing period. For the 6 days of
testing, the data from the last 2 days (day 5 and day 6) is
used to determine the effect of genotype and/or treat-
ment on impulsivity. The number of times the small re-
ward is chosen on day 5 and day 6, out of 12 total trials,
is compared. To ensure observers were blind to geno-
type conditions, animal cages were letter-coded prior to
behavioral testing. For Experiment 2, VEH (n = 6/geno-
type) and 0.3 mg/kg GUAN (n = 6/genotype) were ad-
ministered to a separate cohort of DDT trained WT and
Nf1+/− mice immediately prior to the start of each test-
ing day (across 6 days in total). Since DDT training and
testing can take up to 4 weeks, we chose to use only the
0.3 mg/kg GUAN dose for this test. All data were re-
corded by an observer blind to the treatment conditions.
Statistical analysis
Open field data were analyzed using a two-way ANOVA
with repeated measures with genotype as the main factor
and time as repeated measures. Total distance traveled
during the entire test period in the open field test were
expressed as mean + SEM and analyzed with a Student’s
t test. In the CAR test, a Student’s t test was used to as-
sess the effect of genotype on the distance traveled dur-
ing the CAR test as well as stereotypy and ataxic scores.
Furthermore, a Chi square test was used to assess the ef-
fect of genotype on the percentage of mice that dis-
played CAR impairment. A two-way ANOVA with main
effects of genotype and location was used to analyze the
number of entries into different locations on the CAR
platform. Delay discounting data were analyzed using a
two-way ANOVA with time of delay and genotype as the
main factors, and in the presence of significance, post
hoc analyses were conducted with Sidak’s multiple com-
parisons test. The effects of GUAN on distance traveled
were analyzed using a three-way ANOVA with repeated
measures with genotype and treatment as the main fac-
tors and time as the repeated measures. A Chi square
test was used to assess the effects of GUAN on the % of
mice with intact CAR within each genotype, whereas
total distance traveled and stereotypy scores were ana-
lyzed using a two-way ANOVA with genotype and treat-
ment as the main factors. The effects of GUAN on delay
discounting were assessed using a two-way ANOVA
with treatment and genotype as the main factors. In the
presence of a significant main effect, post hoc analyses
for all ANOVAs were assessed with Sidak’s multiple
comparisons test. Statistical significance was accepted with
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p ≤ 0.05. All statistical analyses were carried out using
GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA) and
SPSS 25.0 (IBM Corp.). All graphs were generated using
GraphPad Prism 7.0. For a significance level of α = 0.05,
using means and standard deviations obtained from prelim-
inary studies, we calculated power using a power calculator
available from “Online Statistics Education: An Interactive
Multimedia Course of Study – XXI:9” (David M. Lane;
jStat, MIT license). For n = 6, open field data resulted in
0.828 power. For n = 6, CAR data resulted in 0.894 power.
For n = 6, DDT data resulted in 0.899 power. Therefore,
these studies are sufficiently powered. The effect size was
determined by taking the difference between the means
and dividing it by the standard deviation. Furthermore, all
data were tested for normality with a Shapiro–Wilk
normality test.
Results
Experiment 1: Phenotyping Nf1+/− mice for ADHD-
associated behaviors
One hour open field
Nf1+/− mice exhibit increased distance traveled during
the 60-min testing period compared to WT mice (Fig.
1a, b). A two-way ANOVA with repeated measures re-
vealed main effects of time (F5,65 = 17.51, p < 0.0001)
and genotype (F1,13 = 9.707, p = 0.0082) without a
time × genotype interaction (F5,65 = 1.996, p = 0.0908).
Post hoc analyses of between subject effects at every
10-min time segment demonstrated that Nf1+/− mice
exhibit increased total distance traveled at 20 min (p =
0.0113), 30 min (p = 0.0224), 50 min (p = 0.0021), and
60 min time points (p = 0.0010; Fig. 1a). Overall, Nf1+/−
mice exhibit an increased amount of total distance trav-
eled within the total 60-min testing period (t = 3.116,
df = 13, p = 0.0082; Fig. 1b).
Cliff avoidance reaction (CAR) test
Nf1+/− mice had an increased amount of total distance trav-
eled during the 60-min CAR test compared to WT mice
(t = 2.529, df = 10, p = 0.0299), once again suggesting hyper-
activity in Nf1+/− mice (Fig. 2a). Comparing the number of
entries into the center and edges of the platform, a two-way
ANOVA found main effects of location (F1,22 = 5.672, p =
0.0263) and genotype (F1,22 = 16.3, p = 0.0006), but not an
interaction between location and genotype (F1,22 = 0.5208,
p = 0.4781). Nf1+/− mice exhibited an increased number of
entries (p = 0.0285) into the edge zone of the platform com-
pared to WT (p = 0.2702; Fig. 2b). In addition, Nf1+/− mice
placed a large portion of their heads and torsos over its
edge and made an increased amount of entries into the
over the edge zone where they attempted to climb under-
neath the platform (p = 0.0028) compared to WT controls
(p = 0.0324; Fig. 2b). These data suggest that Nf1+/− mice
display increased deficits in behavioral inhibition, and it
was common for Nf1+/− mice to fall off the platform. Falling
at least once from the platform is referred to as impaired
CAR. Over half of the Nf1+/− mice exhibited impaired CAR
during the 60-min test (Fig. 2c). However, no WT mice dis-
played impaired CAR (Fig. 2c). This was confirmed by a
significant difference of % mice with intact CAR between
WT and Nf1+/− mice (Chi square = 54.78 (1), p < 0.0001).
In addition, stereotypy scores of Nf1+/− mice were signifi-
cantly higher than those of WT mice (t = 3.544, df = 11, p =
0.0046; Fig. 2d). However, neither WT nor Nf1+/− mice
showed any significant signs of ataxic behavior (data not
shown; all animals regardless of genotype received a 0
score). These data suggest an impulsive phenotype in
Nf1+/− mice.
Delay discounting test
In the delayed discounting test (Fig. 3), a two-way
ANOVA revealed main effects of delay (F2,50 = 130.2,
Fig. 1 Nf1+/− mice exhibit hyperactivity in response to a novel open field. Graphs depict the differences in behaviors between WT and Nf1+/−
mice on the a distance (m) traveled over time, and the b total distance moved (m) in 60 min. *p < 0.05 compared to wild-type (WT). All data
reported as mean + S.E.M
Lukkes et al. Journal of Neurodevelopmental Disorders            (2020) 12:2 Page 5 of 13
p < 0.0001) and genotype (F1,50 = 60.98, p < 0.0001) as
well as an interaction between delay and genotype
(F2,50 = 20.8, p < 0.0001). Post hoc analyses suggest that
upon delayed initiation, both WT and Nf1+/− mice se-
lected the smaller reward more frequently (p < 0.0001;
Fig. 3b). Nf1+/− mice chose an increased number of
smaller reinforcements at both the 10 and 20 s delay
compared to WT controls (p < 0.0001), suggesting in-
creased impulsivity in Nf1+/− mice.
No significant differences were found for the number
of days required to reach criterion because of genotype
(F1,24 = 1.185, p = 0.2872; Fig. 3c). There was a main ef-
fect of delay (F1,24 = 6.41, p = 0.0183) but no interaction
between delay and genotype (F1.24 = 2.278, p = 0.1442). On
average, Nf1+/− mice required 10.29 ± 1.02 days to reach
criterion, whereas WT mice required 12.60 ± 0.68 days for
the 10 s delay (Fig. 3c). For the 20 s delay test, Nf1+/− mice
required 9.38 ± 0.84 days to reach criterion, whereas WT
mice required 9.00 ± 0.82 days. These data suggest that the
Nf1 mutation did not produce learning or motivational
deficits in this reward-driven behavioral test.
Experiment 2: Determining the effects of GUAN on
ADHD-associated behaviors in Nf1+/− mice
One hour open field with GUAN administration
Nf1+/− mice treated with VEH exhibit increased distance
traveled in response to a novel open field compared to
WT (Fig. 4a, b). A three-way ANOVA with repeated
measures revealed main effects of time (F5,195 = 28.750,
p < 0.0001) as well as a time × treatment interaction
(F5,195 = 4.150, p < 0.0001). However, no main effects of
genotype nor other interactions were observed (all p >
0.05). In VEH-treated animals, post hoc analyses revealed
that Nf1+/− mice exhibit increased total distance traveled at
20 and 40 min compared to WT mice (p < 0.05; Fig. 4a).
Administration of 0.1 and 0.3 mg/kg GUAN over 6 days
decreased the total distance moved over time in both
Nf1+/− and WT mice (p < 0.05; Fig. 4a). A two-way
ANOVA revealed main effects of treatment (F2,41 = 51.58,
p < 0.0001) as well as a genotype × treatment interaction
(F2,41 = 9.525, p = 0.0098), but no main effects of genotype
(F1,41 = 2.106, p = 0. 1375) in the open field test for total dis-
tance moved during the 60-min testing period (Fig. 4b).
CAR test with GUAN administration
Administration of 0.3 mg/kg GUAN for 6 days prior to
the CAR test attenuated impairments in behavioral inhib-
ition observed in Nf1+/− mice throughout the test (Fig. 5).
A two-way ANOVA found main effects of treatment
(F2,42 = 27.56, p = 0.0003) and genotype (F1,42 = 9.917, p =
0.0114), but not an interaction between treatment × geno-
type (F2,42 = 4.006, p = 0.2544) in the CAR test on total
distance traveled during the 60-min testing period. Nf1+/−
mice exhibited increased total distance traveled following
VEH administration compared to VEH-treated WT mice
(p = 0.018; Fig. 5a). Administration of 0.3 mg/kg GUAN
Fig. 2 Nf1+/− mice exhibit deficits in behavioral inhibition in the cliff avoidance reaction (CAR) test. Graphs illustrate the effects of Nf1+/− on the a
total distance traveled (m), b number of entries made into the edge zone and outer edge zone of the CAR platform, c % mice with intact CAR,
and d stereotypy rating scores. *p < 0.05 compared to wild-type (WT). All data reported as mean + S.E.M
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attenuated the higher total distance traveled observed in
Nf1+/− mice (p < 0.021) but had no effect on WT mice (p >
0.9999; Fig. 5a). In contrast, administration of 0.1 mg/kg
GUAN increased distance traveled in Nf1+/− mice com-
pared to WT (p = 0.0285). More than half of the Nf1+/−
mice exhibited impaired CAR during the 60-min test (Fig.
5b). Compared to VEH-treated WT, VEH-treated Nf1+/−
mice more frequently exhibited impaired CAR (p < 0.0001;
Fig. 5b). Administration of GUAN did have dose-
dependent effects on CAR performance (Chi square = 18.99
(2), p < 0.0001). Administration of 0.3 mg/kg GUAN but
not 0.1 mg/kg GUAN improved impaired CAR in Nf1+/−
mice (p < 0.05; Fig. 5b). In addition, a two-way ANOVA
found main effects of treatment (F2,48 = 24.52, p = 0.0002)
and genotype (F1,48 = 14.05, p= 0.0012) on stereotypy score,
with a non-significant treatment and genotype interaction
(F2,48 = 4.444, p= 0.1649) on stereotypy score (Fig. 5c). Post
hoc tests revealed that 0.3 mg/kg GUAN administration de-
creased stereotypy score in Nf1+/− mice (p= 0.0007; Fig. 5c).
No differences were observed in ataxic behavior regardless
of genotype and treatment (data not shown; all animals re-
ceived a 0 score).
Delay discounting with GUAN administration
Administration of GUAN to Nf1+/− mice attenuated the
amount of delay discounting to WT control levels (Fig. 6).
Since Nf1+/− mice exhibited similar behavior in response to
both the 10- and 20-s delays, we chose to only investigate
the effects of GUAN administration on impulsive choice in
response to the 10-s delay (Fig. 3b). A two-way ANOVA
Fig. 3 Nf1+/− mice exhibit increased impulsive choice in the delay discounting test (DDT). Graphs illustrate a the general methods used in the
DDT on a t-maze and the effects of Nf1+/− on b the number of small reinforcements chosen during a DDT task in a t-maze and c the number of
days the mice took to reach criterion prior to the initiation of the delay. *p < 0.05 compared to wild-type (WT). #p < 0.05 compared to 0 delay
within the same genotype. All data reported as mean + S.E.M
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revealed main effects of treatment (F3,36 = 39.51, p < 0.0001)
and genotype (F1,36 = 16.84, p < 0.0001) as well as an
interaction between treatment and genotype (F3,36 = 19.52,
p < 0.0001). Post hoc analyses suggest that upon initiation
of a 10-s delay, both VEH-treated WT and Nf1+/− mice se-
lected the smaller reward more frequently (p < 0.0001; Fig.
6a). However, Nf1+/− mice treated with VEH chose an in-
creased number of smaller reinforcements in response to
the 10-s delay compared to WT controls (p < 0.0001; Fig.
6a). These data confirm that the Nf1+/− mutation leads to
increased impulsivity. GUAN treatment decreased the
number of small reinforcements Nf1+/− mice chose in re-
sponse to the 10-s delay compared to VEH-treated Nf1+/−
mice (p < 0.05; Fig. 6a).
No significant differences were found for the number
of days required to reach criterion as a result of geno-
type (F1,19 = 0.05266, p = 0.8210) and treatment (F1,19 =
0.7316, p = 0.4030; Fig. 6b). Furthermore, there was not
a significant interaction between treatment and genotype
(F1,19 = 03525, p = 0.8531). These data suggest that the
Nf1+/− mutation did not produce learning or motiv-
ational deficits in this reward-based behavioral test.
Discussion
A high percentage of NF1 children are diagnosed with
ADHD [3, 53]. Furthermore, NF1 children tend to be im-
pulsive and struggle with social cues, which can lead to
poor scholastic performance [54–57]. In this study, we re-
port for the first time that mutation of the NF1 gene in
male mice leads to hyperactivity, impulsivity, and deficits in
behavioral inhibition. We also show that treatment with a
commonly used non-stimulant ADHD medication, GUAN,
attenuates these deficits in Nf1+/− mice.
Nf1+/− mice exhibited increased distance traveled com-
pared to WT controls in a 1-hr open field test. These
Fig. 4 Guanfacine (GUAN) decreases hyperactivity in Nf1+/− mice. Graphs depict the effects of GUAN (0.1 and 0.3 mg/kg) on the a amount of
distance (m) traveled over time and the b total distance moved (m) in 60 min. *p < 0.05 compared to wild-type (WT) within the same treatment.
#p < 0.05 compared to vehicle (VEH) within the same genotype. All data reported as mean + S.E.M
Fig. 5 Guanfacine (GUAN, 0.3 mg/kg) attenuates deficits in behavioral inhibition in Nf1+/− mice in the cliff avoidance reaction (CAR) test. Graphs
illustrate the effects of Nf1+/− on the a total distance traveled (m), b % mice with impaired CAR, and c stereotypy rating scores. *p < 0.05
compared to wild-type (WT) within the same treatment. #p < 0.05 compared to vehicle (VEH) within the same genotype. All data reported
as mean + S.E.M
Lukkes et al. Journal of Neurodevelopmental Disorders            (2020) 12:2 Page 8 of 13
data suggest that Nf1+/− mice exhibit hyperactivity in an
open field compared to WT mice. Furthermore, Nf1+/−
mice may also be displaying a lack of habituation to the
novel open field environment since a similar level of
locomotion compared to WT mice was observed in the
first 10 min of the open field test. In contrast to our
current findings, previous studies have found that Nf1+/−
OPG mice display decreased total ambulation and re-
duced exploratory behavior in a novel environment [38].
In general, these data suggest that both Nf1+/− and
Nf1+/− OPG mice display abnormal locomotor activity.
Differences in locomotor activity may be explained by
the unique genetic engineering of the models. While
Nf1+/− mice used in this study are haploinsufficient in all
cells, Nf1+/− OPG mice are haploinsufficient in all cells
except for GFAP+ cells that are Nf1−/−. Due to the role
that glial cells play in neurodevelopment and mainten-
ance, it can be expected that there would be some be-
havioral differences in these models. In particular,
Brown et al. [38] suggest that Nf1+/− neurons and Nf1−/−
glial cells both contribute to dopamine (DA) homeosta-
sis, so we have two distinctive models to study the role
of DA and norepinephrine (NE) in NF1 and how the
interaction of glial cells contribute to the regulation of
these neural systems and resulting behaviors. Nf1+/−
OPG mice provide the unique experimental model of
studying the role of astrocytes in behavior, while Nf1+/−
mice provide an experimental model for the wider NF1
clinical population. Hyperactivity is a core symptom
found in patients with ADHD as well as NF1 patients di-
agnosed with ADHD [19, 35]. This hyperactivity in
Nf1+/− mice was reduced with both 0.1 and 0.3 mg/kg
GUAN administration. In general, we did observe re-
duced distance traveled in response to GUAN treatment
regardless of genotype or dose over time. GUAN may be
having biochemical effects both centrally and peripher-
ally on the α2A adrenoceptors that contribute to this ob-
served behavior modulation [58]. The most common
adverse effects reported with GUAN studies in ADHD is
sedation [59], which could also be contributing to some
of the reduction in distance traveled in WT mice. While
sedation may be having an effect, it is well established
that GUAN improves hyperactivity and attention inde-
pendent of sedation.
Nf1+/− mice exhibited increased hyperactivity and im-
pulsivity compared to WT mice in the CAR test. In-
creased entries into the edge and outer edge zones of
the platform where mice risk falling was observed more
frequently in Nf1+/− mice. Furthermore, Nf1+/− male
mice displayed impaired CAR, increased total distance
moved, and high levels of stereotypical behavior during
CAR testing compared to WT mice. It is important to
note that impaired CAR observed in Nf1+/− mice may be
a result of their overall hyperactivity and possible lack of
habituation to the novel environment. Moreover, in-
creased stereotypic behavior, such as sniffing along a
fixed path, may have brought Nf1+/− mice to the edge
more frequently and played a role in the observed CAR
impairment. Repeated treatment with GUAN had dose-
dependent effects in the CAR test. Administration of the
lower 0.1 mg/kg GUAN dose increased total distance
traveled in the CAR test regardless of genotype, but did
not have significant effects on the % mice with intact
CAR or stereotypy score. However, treatment with 0.3
mg/kg GUAN ameliorated these behavioral deficits in
Nf1+/− mice. Since there was not a significant effect of
0.3 mg/kg GUAN on distance traveled in WT mice dur-
ing the CAR test, our data suggest that the beneficial ef-
fects of 0.3 mg/kg GUAN in Nf1+/− mice may be
independent from a sedative action. However, it is
Fig. 6 Guanfacine (GUAN, 0.3 mg/kg) decreases impulsive choice in Nf1+/− mice in the delay discounting test (DDT). Graphs depict the effects of
GUAN on a the number of small reinforcements chosen during a DDT task in a t-maze and b the number of days the mice took to reach
criterion prior to the initiation of the delay. *p < 0.05 compared to wild-type (WT) within the same treatment. #p < 0.05 compared to vehicle (VEH)
within the same genotype. All data reported as mean + S.E.M. Black-filled bars represent WT mice treated with VEH. Green-filled bars represent
Nf1+/− mice treated with VEH. Gray-filled bars with pattern represent WT mice treated with GUAN. Green-filled bars with pattern represent Nf1+/−
mice treated with GUAN
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possible that the lower general activity observed in ani-
mals treated with 0.3 mg/kg GUAN may have led to less
exploration of the outer edge, thereby decreasing the
chance that the mice would fall off. Overall, these
data from the CAR test recapitulate a core symptom
of ADHD observed in NF1 patients: deficits in re-
sponse to inhibition [2, 30, 60]. In different experi-
mental and clinical models, GUAN improves working
memory and regulates attention, cognitive perform-
ance, and behavioral inhibition [61, 62]. These data
provide predictive validity for Nf1+/− mice as a strong
preclinical experimental model of deficits in behav-
ioral inhibition found in NF1 patients.
Increased impulsive behavior in Nf1+/− male mice was
also observed in a DDT that was attenuated by 0.3 mg/
kg GUAN treatment. Nf1+/− mice chose a higher per-
centage of smaller rewards with both 10 and 20-s delays
compared to WT mice, suggesting Nf1+/− mice are more
impulsive. When treated with GUAN (0.3 mg/kg, i.p.)
daily across the 6-day testing phase of the DDT, Nf1+/−
mice exhibited decreased impulsive choice by waiting for
the larger, delayed reward more frequently. Our data are
in line with some of the clinical ADHD phenotype ob-
served in NF1 patients. In the Go/No-Go task, a task
that tests the ability to control impulsive behavior [63],
individuals with NF1 commit more errors and respond
faster than controls without NF1 [35]. In general, faster
responses in the Go/No-Go task suggest a less cautious,
more impulsive strategy that are indicative of deficits in
impulse control [35]. Furthermore, reduced activation of
the prefrontal cortex (PFC) during inhibition of re-
sponses during a Go/No-Go task was observed in NF1
patients [54]. Administration of GUAN moderated the
influence of affective cues on response execution in the
Go/No-Go task [58]. In monkeys, GUAN also promotes
delay in the most important rewards as compared to im-
mediate rewards, and improves impulse control [64].
Overall, GUAN has reduced impulsive behavior in clin-
ical studies of ADHD and in preclinical studies of NF1;
our data confirms the efficacy of this treatment for the
first time in a preclinical NF1 model.
NF1 is likely to cause a variety of structural, functional,
and neurochemical alterations in the central nervous
system that are associated with the learning impairments
observed in patients with NF1 [34, 65]. The results of
the studies reported here support that Nf1+/− mice are a
useful experimental model for studying behavioral inhib-
ition, and to elucidate the underlying mechanisms. For
example, abnormal inhibition, especially related to
GABAergic neurotransmission in NF1 patients may
underlie some of their cognitive impairments associated
with ADHD [35]. For instance, magnetic resonance
spectroscopy found decreased GABA levels in the medial
frontal cortex of NF1 patients [35]. However, a
correlational analysis done in this same study suggest
that high GABA was associated with a faster response
style in NF1 patients in the Go/No-Go task, whereas a
more cautious strategy was found in control patients
[35]. In Nf1+/− mice, increased inhibitory drive was ob-
served throughout the brain [64–66]. This is consistent
with numerous preclinical studies of NF1 mouse models
reporting that GABA tone is notably higher in key brain
regions including the prefrontal cortex, striatum, amyg-
dala, and hippocampus [20, 22, 67–69]. This altered ex-
citation/inhibition balance is linked to cognitive deficits
in NF1 mouse models that mirror deficits observed in
NF1 patients [20, 40, 68]. Therefore, aberrant GABAer-
gic signaling may underlie the deficits in behavioral in-
hibition observed in the current study. How selectively
modulating noradrenergic neurotransmission with
GUAN regulates this inhibitory abnormality to restore
function is an important objective to further elucidate
the structural, functional, and neurochemical alterations
occurring in NF1. Okada and colleagues have started in-
vestigating this and suggest that GUAN has dual actions
on noradrenergic transmission via GABAergic disinhib-
ition in the orbitofrontal cortex [70].
Dysfunction of the DA and/or NE nervous systems is
a commonly accepted mechanism that leads to ADHD
[71]. This dysfunction is also evident in NF1 models.
Preclinical studies in Nf1+/− OPG mice have found im-
paired DA homeostasis, such as reduced DA levels, post-
synaptic DA signaling, and presynaptic DAT expression
in the striatum [38]. Furthermore, DA innervation in the
hippocampus was also disrupted in Nf1+/− OPG mice as
well as hippocampal D1/D5 DA receptor function [37,
72–75]. It is important to note that these alterations in
DA levels were only evident in Nf1+/− OPG mice that
have inactivation of neurofibromin in GFAP+ cells [38].
The stimulant, methylphenidate (MPH), increases extra-
cellular catecholamine levels by blocking DA and NE re-
uptake via the DA transporter (DAT) [76, 77] and/or NE
transporters (NET) in a region-specific manner [58, 59].
Previous studies examined the effects of MPH in NF1
children with attention problems [53]. In Nf1+/− OPG
mice, treatment with MPH increased striatal DA levels,
restored attention deficits, and ameliorated spatial learn-
ing deficits [38, 78]. Alterations in DA levels, signaling,
and expression in the Nf1+/− mouse experimental model
used in the current study have yet to be investigated.
Studies are currently being conducted in our laboratory
to investigate dopamine and norepinephrine systems in
the Nf1+/− mouse model that may uncover insights into
these systems and their roles in both NF1 and in ADHD.
Treatments for ADHD have mainly been focused on
using psychostimulants such as MPH or amphetamine
that act primarily on catecholaminergic presynaptic
mechanisms [62]. However, the non-stimulant GUAN
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for the treatment of ADHD is also well accepted. We
chose to investigate the effects of GUAN on measures of
hyperactivity and impulsivity in the current study be-
cause GUAN has clinical efficacy in the treatment of
ADHD, and yet, few preclinical studies have investigated
its effectiveness in a preclinical model of NF1. GUAN
binds α2A adrenoceptors on postsynaptic dendritic
spines of prefrontal pyramidal cells, strengthening pre-
frontal cortex (PFC) circuits [62, 66]. Specifically, at the
postsynaptic level, GUAN inhibits cyclic adenosine
monophosphate (cAMP) production and closes HCN
and KCNQ potassium channels to enhance signals from
pyramidal neurons in the PFC [79, 80]. As the PFC plays
a critical role in executive function and alterations in
this area underlie symptoms of ADHD, augmentation of
the PFC reduces ADHD behaviors. Thus, GUAN may
address two key targets: improving functionality of the
PFC and influencing noradrenergic function [62, 81]. Be-
havioral deficits, such as increased impulsiveness, hyper-
activity, and poor attention, are restored following the
administration of α2A adrenergic agonists, such as
GUAN [63, 82]. Therefore, it can be inferred that en-
dogenous production of NE is significant to α2A receptor
regulation of the PFC [62, 83]. For instance, iontopho-
retic delivery of GUAN into the PFC increases delay in
neuronal discharges; this delay is essential for enhancing
working memory [84]. Moreover, neuroimaging studies
in primates and humans have observed that GUAN ad-
ministration increased blood flow in the PFC as well as
improved working memory, only affecting areas related
to cognitive performance [85]. Future studies will need
to examine catecholamine levels in Nf1+/− mice and α2A
receptors within the PFC as well as how GUAN acts on
these systems to improve ADHD-associated behaviors.
Conclusions
Our study is the first to show that Nf1+/− mice exhibit
reduced behavioral inhibition leading to increased im-
pulsivity. Furthermore, it is the first preclinical study to
show that GUAN treatment can attenuate the observed
impairments in Nf1+/− mice. Overall, our study confirms
that Nf1+/− mice exhibit deficits in behavioral inhibition,
a key feature of ADHD, that are amenable to pharmaco-
logical therapies used clinically for ADHD. These data
suggest that Nf1+/− mice are a useful experimental
model to identify alterations in neural circuitry associ-
ated with core symptoms of ADHD.
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